Human beings are about to be merged with the “cloud” in a new clinical trial involving brain-machine interfaces.
Synchron, a competitor of Elon Musk’s Neuralink Corp., just enrolled the first patient in its United States-based clinical trial. If successful, the company could soon receive regulatory approval for wide use in the human population.